Royalty Report: Drugs, Disease, Therapeutic – Collection: 233451

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diabetes Treatment
  • obesity
  • Cancer
  • Parkinsons Disease
  • Diagnostic
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 203313

License Grant
Licensor grants an exclusive, even as to Licensor, world-wide license under the Patent Rights and the Know-How to develop, make, have made, use, sell, have sold, offer for sale, import or otherwise commercialize Licensed Products and Improvements in the Field.
License Property
The Compounds shall mean doxepin, amitriptyline, trimipramine, trazodone and nortriptyline, as well as any respective prodrugs, hydrates, salts, esters, isomers, polymorphs or analogues thereof.

'Patent Rights' shall mean (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487

Field of Use
The Field shall mean the prevention, treatment or control of insomnia, and any other use of the Compounds within the Ranges.

IPSCIO Record ID: 215177

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory, with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense in conjunction with a sublicense permitted by this agreement, to use the Licensors Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 203477

License Grant
Pursuant to this agreement, the Parties agree to collaborate on an exclusive basis in the Development and Commercialization of Product in the Field.

Licensor grants an exclusive license in the Territory except for the U.S. with the right to sublicense, under the Licensor Rights existing as of the Effective Date, solely to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Field in the Territory except for the U.S. as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Licensor grants a non-exclusive, worldwide license, including the right to sublicense, to use the Licensor Marks on Product packaging, labeling, advertising and Promotional Material.

For IT improvements, Licensor grants a worldwide, nonexclusive license in the Territory to practice under the rights of Licensor to any such Licensor Rights and Improvements to develop, make, have made, use, sell, offer for sale, have sold and import Compound and Product in the Territory as contemplated by this Agreement, and otherwise to perform its obligations expressly set forth in this Agreement or the Related Agreements in the Territory.

Each Party hereby grants the other Party an exclusive option to enter into an agreement for the Development of Option Compound(s) Controlled by the granting Party.

License Property
The Neogenesis patents are claiming differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4.

The Compound means exendin-4, an amino acid sequence.

AC2993 (synthetic exendin-4) is a peptide that has been shown to stimulate insulin secretion when blood glucose concentrations are high, but not when blood glucose levels are low.

The Product means a pharmaceutical product that contains or incorporates Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration (including, without limitation, all delivery devices or other peripherals and consumables).

U.S. 5,424,286

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.

This collaboration agreement is for development and sale of a potential new treatment for type 2 diabetes.

IPSCIO Record ID: 233443

License Grant
For the exclusive license, Licensor grants to the Licensee of Bermuda an exclusive license, even as to Licensor, in the Territory under Licensor Patent Rights, Licensors and its Controlled Affiliates rights in Joint Patent Rights, and Licensor Know-How, with a right to sublicense, to make, have made, use, offer to sell, sell or import Compound(s) and Product(s) in the Field.

For the Non-Exclusive License Grants  Licensor grants to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under any such issued patent for Licensee to make, have made, use, sell, offer for sale or import Compound(s) and Product(s) in the Territory.

And, Licensor grants a non-sublicenseable, non-exclusive license to use Licensor 102,677 for the purpose of developing an assay relating to Licensor 21,947 that quantifies the level, if any, of Licensor 102,677 present in Licensor 21,947 in vitro or in vivo.

License Property
The patents and know-how are for compounds for the treatment and/or prevention of anxiety and/or depression.

Compound shall mean Licensor 21,947, and/or Licensor 216,303. For avoidance of doubt, Compound does not include Licensor 102,677.

Licensor 21,947 shall mean the compound having a chemical name (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. l .0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.

Licensor 102,677 shall mean the compound having a chemical name (-)-l-(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.

Licensor 216,303 shall mean the compound having a chemical name (±)-l -(3,4-dichlorophenyl)-3-azabicyclo[3. I.0]hexane, including all solvates, Prodrugs, salts and polymorphs thereof.

Field of Use
The Field shall mean in the case of 21,947, the use of 21 ,947 and/or pharmaceutical preparations in final form containing 21,947 for the treatment and/or prevention and/or diagnosis of diseases and/or medical conditions in humans and/or animals; and in the case of 216,303, the use of 216,303 and/or pharmaceutical preparations in final form containing 216,303 for the treatment and/or prevention and/or diagnosis of depression, anxiety or addiction in humans and/or animals.

IPSCIO Record ID: 257486

License Grant
The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents, to the extent, but only to the extent, that such patents or patent applications claim the Compound or Product or the manufacture, formulation, or use thereof, and Know-How to develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the Territory, subject to the terms and conditions of this Sublicense Agreement.

Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.

Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.

License Property
Licensor has rights to certain patents and patent applications, and know-how relating to a compound known as Iloperidone.

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Field of Use
The Field shall mean application to all conditions, disorders and diseases in humans.  The licensed property use is for therapeutic treatment of schizophrenic patients.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 204310

License Grant
This agreement is for the reversion to Licensee of the rights for the Commercialization of Compound and Products in the United States, including the rights to Commercialize Co-Formulation Products in the United States.

The Licensor of England grants back to Licensee the following licenses, with the right to grant sublicenses, under all Program Improvements and Program Patents  
(i) a co-exclusive license to Develop Products in the Field and in the Territory,
(ii) subject to Licensor’s rights and obligations to Manufacture Products for Development activities, an exclusive license, exclusive even as to Licensor, to make and have made and otherwise Manufacture Compound and Products, other than Co-Formulation Products, in the Field and anywhere in the Territory for the Licensee Territory; and
(iii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Products in the Field in the Licensee Territory.

Licensor grants the following licenses, with the right to grant sublicenses, under the Co-Formulation Product IP
(i) a co-exclusive license to Develop Co-Formulation Products in the Field in the Territory, and
(ii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Co-Formulation Products in the Field in the Amicus Territory.

Licensor grants to Licensee a worldwide, non-exclusive, right and license, with the right to grant sublicenses,
(a) under Licensor’s and its Affiliates’ rights in the Program Patents to make, have made, use, sell, offer for sale, and import products, and to otherwise practice and exploit the Program Improvements and
(b) under Licensor’s and its Affiliates’ rights in the Patents within the Co-Formulation Product IP to make and have made, other than JR051 or Co-Formulation Product in which the ERT enzyme is JR051, use, sell, offer for sale and import products, other than JR051, and to otherwise practice and exploit the Patents within the Co-Formulation Product IP claimed in such Program Patents and/or Patents within the Co-Formulation Product IP.

In the original agreement, Amicus granted to Licensee exclusive, worldwide, rights to Compounds and Products (each as defined below) and pursuant to which Amicus and GSK have collaborated and are collaborating on the Development of the Compound and Product;

License Property
The Compound means migalastat, and includes (a) any compounds with alternative names but with the same chemical structure as migalastat, and (b) any metabolites, prodrugs, isomers and enantiomers, excluding the isomer/enantiomer 1-deoxynorjirimycin or (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol, esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

The Co-Formulation Product ERT Enzyme means JR051; or any other alpha Galactosidase A enzyme selected by the Parties to be used as a ERT enzyme in co-formulation with the Compound.  ERT means enzyme replacement therapy.

Co-development of all current and future formulations of migalastat HCl for Fabry disease, including a co-formulation of migalastat HCl with Licensee’s investigational enzyme replacement therapy (ERT) for Fabry disease.

Fabry disease is a rare genetic disease a deficiency of the enzyme alpha-galactosidase A (a-Gal A) that causes a buildup of a type of fat called globotriaosylceramide (Gb3, or GL-3) in the body. Fabry disease is classified as a type of lysosomal storage disorder.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with ERT.

IPSCIO Record ID: 372427

License Grant
Swiss Licensor hereby grants to Bermuda Licensee an exclusive, sublicensable (Sublicensing), royalty-bearing right and license under the Licensor Technology and Licensor’s interest in the Joint Technology to Exploit the Licensed Compounds and Licensed Products in the Field in the Licensee Territory.

Licensor hereby grants to Licensee a non-exclusive, sublicensable (Sublicensing) right and license under the Licensor Technology and Licensor’s interest in the Joint Technology to (a) Develop the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Licensor Territory solely for the purpose of Exploiting such Licensed Products in the Field in the Licensee Territory, or as required in order for Licensee to comply with its diligence obligations set forth in Agreement (Development Diligence Obligations) and (b) Manufacture the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Licensor Territory.

Licensor hereby grants to Licensee (or its Affiliates or its Sublicensees) access to, and a right of reference with respect to, any Licensor Regulatory Materials and corresponding documentation to the extent Controlled by Licensor at any time during the Term, solely for the purposes of (a) Exploiting the Licensed Compounds and Licensed Products in the Field in the Licensee Territory, (b) Developing the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Licensor Territory, and (c) Manufacturing the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Licensor Territory.

License Property
Licensed Product means any TAK-385 Licensed Product or TAK-448 Licensed Product.

TAK-385 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-385 Licensed Compound.

TAK-448 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-448 Licensed Compound.

Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

TAK-385 Licensed Compound means (a) the chemical compound coded by Licensor as TAK-385 and the structure of which is set forth in Agreement (TAK-385 Licensed Compound); (b) any compound other than TAK-385 that is Covered by any Licensor Patent Right set forth in Agreement (Licensor Patent Rights) that also Covers TAK-385; and (c) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

TAK-448 Licensed Compound means (a) the oligopeptide coded by Licensor as TAK-448 and the structure of which is set forth in Agreement (TAK-448 Licensed Compound); (c) any oligopeptide other than TAK-448 that is Covered by any Licensor Patent Right set forth in Agreement (Licensor Patent Rights) that also Covers TAK-448; and (d) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

Licensor Patent Rights means (a) those Patent Rights set forth in Agreement part (a) (TAK-385 Patent Rights), (b) those Patent Rights set forth in Agreement part (b) (TAK-448 Patent Rights), and (c) all Patent Rights (other than Licensee Patent Rights and Joint Patent Rights) Controlled by Licensor during the Term that Cover any Invention made by or on behalf of Licensor after the Effective Date that Covers a Licensed Compound or any Licensed Product or is otherwise necessary to Exploit any Licensed Compound or Licensed Product.

Field of Use
Field means the treatment, prevention, cure, or control of any human disease, disorder, illness, or condition, including the Men’s Health Field and the Women’s Health Field.

Men’s Health Field means the treatment, prevention, cure, or control of symptoms associated with prostate cancer.

Women’s Health Field means the treatment, prevention, cure, or control of symptoms associated with Uterine Fibroids or Endometriosis.

IPSCIO Record ID: 203304

License Grant
The Israeli Licensor grants a non-exclusive, worldwide license to all Intellectual Property Rights solely for the manufacture, development, formulation, use, sale, offer for sale, and importation of finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, any aspect of such rights which purport to cover or relate to PROVIGIL®, SPARLON® and/or NUVIGIL®]
License Property
Modafinil Product shall mean all finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, PROVIGIL®, SPARLON® and NUVIGIL®, sold by Licensee, its Affiliates, distributors and resellers.
Field of Use
This agreement is for the pharmaceutical industry, with specific applications for attention-deficit/hyperactivity disorder ADHD in children and adolescents, excessive sleepiness and Parkinsons Disease.

IPSCIO Record ID: 211925

License Grant
The Canadian Licensor grants an exclusive license under the Licensors Technology to use, market, advertise, promote, distribute, offer for sale, sell, manufacture, have manufactured, export and import, and co-develop the Product in the Territory for use in the Field with the right to sublicense.
License Property
The license includes patent rights and know-how for the compound.

The product is the proprietary compound known as ORI-9020.  ORI-9020 means ORI-9020 and its analogs, the chemical composition of which are described in the patent and any prodrug, metabolite, analog, salt, hydrate, solvate, polymorph, chimeric or inverted chimeric or isomer of ORI-9020.

Field of Use
The Field means the use of Product in the diagnosis and/or treatment of Hepatitis B infection.

IPSCIO Record ID: 215205

License Grant
This agreement is for the reversion to Licensor of the rights for the Commercialization of Compound and Products in the United States, including the rights to Commercialize Co-Formulation Products in the United States.

Licensor grants to the English Licensee the following licenses, with the right to grant sublicenses, under the Licensor Technology  a co-exclusive license, co-exclusive with Licensor, to Develop Products in the Field in the Territory, and, an exclusive license to make, have made and otherwise Manufacture Compound and Products in the Field and anywhere in the Territory for the Licensee Territory; and,  an exclusive license to make, have made and otherwise Manufacture Co-Formulation Products in the Field and anywhere in the Territory for the Licensor Territory; and, an exclusive license to Manufacture Compound and Products for use in connection with Development activities; and, an exclusive license to use, sell, offer for sale, import and otherwise Commercialize Products in the Field in the Licensee Territory.

License Property
Compound means migalastat, and includes any compounds with alternative names but with the same chemical structure as migalastat, and any metabolites, prodrugs, isomers and enantiomers (excluding the isomer/enantiomer “1-deoxynorjirimycin” or “(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol”), esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

The Co-Formulation Product ERT Enzyme means JR051; or any other alpha Galactosidase A enzyme selected by the Parties, to be used as a ERT enzyme in co-formulation with the Compound.

ERT means enzyme replacement therapy.

Companies jointly to develop proprietary enzyme replacement therapy (ERT) for Fabry disease co-formulated with chaperone migalastat HCl.

Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. Beginning in childhood, this buildup causes signs and symptoms that affect many parts of the body.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with ERT.

IPSCIO Record ID: 369293

License Grant
Licensor hereby grants to Licensee an exclusive (even as against Licensor and its Affiliates), nontransferable (except with respect to the assignment provision in Agreement) limited license during the Term under the Licensed Patents, solely to make, have made (pursuant to Agreement), use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field. (No license, exclusive or nonexclusive, is granted hereunder under the Licensed Patents, except to so make, have made, use, sell, offer for sale and import the Licensed Products in the Territory in and for the Field.)
License Property
Patents
5,874,418 – Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
6,046,177 – Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
6,133,248 – Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Licensed Product means (a) a Compound combined with or formulated using Captisol for ultimate use in humans in a dosage form/formulation, or (b) a pharmaceutical composition that includes a Compound and that is developed with the assistance of or incorporates any then-confidential component of the Captisol Data Package.

Compound means the proprietary Licensee isoflavone-based drug compound known as ME-143 (also known as NV-143) or the proprietary Licensee mitochondrial inhibitor drug compound known as ME-344, or any derivative, homolog, or analog of ME-143 or ME-344 or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.

Captisol Related Compound means Captisol or any derivative, homolog analog of Captisol or any isomer, salt, hydrate, solvate, amide, ester, metabolite or product of any of the foregoing, including without limitation sulfobutylether g(gamma) cyclodextrin sodium salt.

Licensed Product Family means one or more Licensed Products which are based on the same Compound(s) (or any isomers, salts, hydrates, solvates, amides, esters, metabolites, or prodrugs of the foregoing), irrespective of whether such Licensed Products contain different dosage forms, proportions or formulations of such Compound(s), utilize different inactive ingredients and/or are marketed for different indications. Notwithstanding the foregoing, a Licensed Product based on a Compound shall be deemed to be in a distinct Licensed Product Family from a Licensed Product based on the combination of the same relevant Compound with any other active pharmaceutical ingredient. As such, if Licensee develops one Licensed Product with ME-344 as the sole active ingredient with Captisol and also develops another Licensed Product with ME-344 in combination with another active ingredient with Captisol, then two distinct sets of milestone payments shall be potentially due under this Agreement, one for each of such two distinct Licensed Products.

Field of Use
Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Captisol is  for use with the Licensee’s isoflavone-based drug compounds.

ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation.

Field means the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with the exceptions of (i) ocular treatment of any disease or condition with a formulation including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.

IPSCIO Record ID: 253932

License Grant
The Parties now desire for Licensor to return all of the worldwide rights to the Compound and Products to the Licensee.

The Licensor of England grants an exclusive license, exclusive even as to Licensor, under all of Licensors rights in the Program Improvements, Program Patents, and Co-Formulation Product IP, with the right to grant sublicenses
— to Develop the Compound and Products,
— to make, have made, and otherwise Manufacture Compound and Products, excluding such rights with respect to JR051 individually or for use as part of a Co-Formulation Product, and
— to use, sell, offer for sale, import and otherwise Commercialize the Compound and Products, in each case in the Field and in the Territory.

License Property
Monotherapy Product means a Product incorporating the Compound as the sole active ingredient.

Compound means migalastat, and includes any compounds with alternative names but with the same chemical structure as migalastat, and any metabolites, prodrugs, isomers and enantiomers (excluding the isomer/ enantiomer '1-deoxynorjirimycin' or '(2R,3 R,4 R,5S )-2-(hydroxymethyl )piperidine-3 ,4,5- triol'), esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

Co-Administration Product means a product consisting of co-administration of the Compound or a Product with an enzyme replacement therapy, including without limitation JR051, regardless of the order or form in which the co-administration is performed.

Co-Formulation Product means a pharmaceutical preparation that incorporates the Compound formulated together with JR051.

JR051 means the JCR proprietary enzyme alpha-Galactosidase A that is internally referenced by OSK as JR051, including any derivatives or modifications thereof or analogs thereto.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with enzyme replacement therapy.

Migalastat is a drug for the treatment of Fabry disease, a rare genetic disorder.
Fabry disease, also known as Anderson–Fabry disease, is a rare genetic disease that can affect many parts of the body including the kidneys, heart, and skin. Fabry disease is one of a group of conditions known as lysosomal storage diseases.

IPSCIO Record ID: 249743

License Grant
The German Licensor grants a non-transferable, exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements. The foregoing license grant includes the right to make reference to all regulatory approvals, data, filings and correspondence, including DMFs contained within the Licensor Know-How.
License Property
Licensor has been engaged in the development of implitapide as an inhibitor of microsomal triglyceride transfer protein.

Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.

Field of Use
Licensee is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders.

Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both.  Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.

IPSCIO Record ID: 249742

License Grant
The University grants an exclusive, even as to the University, world-wide license to research, develop, commercialize, make, have made, use, import, offer for sale and sell under the University Existing Patents and New Patents, Licensed Products and Materials in all fields during the Term, and under the Assigned Bristol-Myers Squibb Patents and Assigned BMS Technical Information, the Designated Compounds and University Materials in the Field of Use during the Term.
License Property
The patents include Composition Patents, Combination Patents, and, Universitys Existing and New Patents.

Designated Compound means BMS-201,038;  prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and  stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.

The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.

Field of Use
Field of Use means  monotherapy or in combination with other dyslipidemic therapies for treatment of patients with homozygous familial hypercholesterolemia; monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and (d) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypertriglyceridemia unable to reduce TG<1000 on maximal tolerated therapy.

Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.  These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.

IPSCIO Record ID: 381105

License Grant
Bermuda Licensor hereby grants to Swiss Licensee and its Affiliates and its Sublicensees, access to, and a right of reference with respect to, any Licensor Regulatory Materials and corresponding documentation to the extent Controlled by Licensor at any time during the Term, solely for the purposes of (a) Exploiting the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Licensee Territory, (b) Manufacturing the Licensed Compounds and Licensed Products, (c) completing the On-Going Clinical Trials and (d) performing Licensee’s obligations under this Agreement with respect to the Licensed Compounds and Licensed Products in the Field in the Licensor Territory.
License Property
Licensed Product means any TAK-385 Licensed Product or TAK-448 Licensed Product.

TAK-385 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-385 Licensed Compound.

TAK-448 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-448 Licensed Compound.

Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

TAK-385 Licensed Compound means (a) the chemical compound coded by Licensee as TAK-385 and the structure of which is set forth in Agreement (TAK-385 Licensed Compound); (b) any compound other than TAK-385 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-385; and (c) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

TAK-448 Licensed Compound means (a) the oligopeptide coded by Licensee as TAK-448 and the structure of which is set forth in Agreement (TAK-448 Licensed Compound); (c) any oligopeptide other than TAK-448 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-448; and (d) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).

Licensee Patent Rights means (a) those Patent Rights set forth in Agreement part (a) (TAK-385 Patent Rights), (b) those Patent Rights set forth in Agreement part (b) (TAK-448 Patent Rights), and (c) all Patent Rights (other than Licensor Patent Rights and Joint Patent Rights) Controlled by Licensee during the Term that Cover any Invention made by or on behalf of Licensee after the Effective Date that Covers a Licensed Compound or any Licensed Product or is otherwise necessary to Exploit any Licensed Compound or Licensed Product.

Field of Use
Field means the treatment, prevention, cure, or control of any human disease, disorder, illness, or condition, including the Men’s Health Field and the Women’s Health Field.

Men’s Health Field means the treatment, prevention, cure, or control of symptoms associated with prostate cancer.

Women’s Health Field means the treatment, prevention, cure, or control of symptoms associated with Uterine Fibroids or Endometriosis.

Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the uterus.
Endometriosis is a disease of the female reproductive system in which cells similar to those in the endometrium, the layer of tissue that normally covers the inside of the uterus, grow outside the uterus.

relugolix (TAK-385) is a phase 3 drug candidate that has been evaluated in over 1,300 patients to date. Relugolix has successfully demonstrated significant clinical benefit and was generally well-tolerated across multiple, large, randomized phase 2 clinical trials in three different indications. Relugolix is being developed as an oral, once-daily, potential best-in-class gonadotropin-releasing hormone (GnRH) receptor antagonist for uterine fibroids, endometriosis and prostate cancer.

IPSCIO Record ID: 253919

License Grant
The Parties have developed telaprevir and Belgian Licensee has commercialized Incivo (telaprevir) in the Territory under the terms of the Parent Agreement, and the Parties each now wish to further amend the rights and obligations of the Parties under the Parent Agreement and the Website Cooperation Agreement.

The Parent Agreement shall terminate in its entirety as of the Amendment Effective Date.

With this Additional Development License , the Licensor grants a non-exclusive right and license under the Licensor Know-How, Patent Rights and Licensors rights under Joint Patent Rights to Develop and Manufacture VX-950 and Products containing VX-950 in North America.

License Property
VX-950 is a novel inhibitor of the NS3/4A hepatitis C viral protease.

Compound means VX-950, or any Backup Compound that is included in this Agreement, and all of its or their prodrugs and metabolites, its or their stereoisomers and tautomers, and all of the esters, salts, hydrates, solvates, inclusion complexes and polymorphs of any of the foregoing.

Field of Use
The field of use is for hepatitis C.

IPSCIO Record ID: 243432

License Grant
Licensor grants an exclusive license or sublicense even as to Licensor, with the right to grant sublicenses pursuant to Licensor Patent Rights and Know-How to research, develop, make, have made, use, sell, offer to sell, supply, cause to be supplied, import and have imported Licensed Product in the Field in the Territory.

With the Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information, Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense to Licensee Affiliates, to use only for research purposes any and all Licensor Know-How or Confidential Information of Licensor disclosed to Licensee during the Term but not any Licensor Patent Rights, it being understood and agreed that neither Licensee nor any of its Affiliates will have any right or license to use any such Licensor Know-How or Licensor Confidential Information with respect to Compound or Licensed Product after termination of this Agreement and/or in connection with obtaining Regulatory Approval of a pharmaceutical product and/or the sale or manufacture for sale of any pharmaceutical product.

License Property
Compound means Licensors-1070 and all modifications, enhancements, improvements and backups which result in a heterobifunctional, pan selectin antagonist comprised of a selectin antagonist linked to a benzy amino sulfuric acid (BASA)  and mimicking the native glycosulfopeptide ligand for E and P – selectins and all isomers, tautomers, enantlomers, hydrates, esters, racemates, polymorphs, metabolites, prodrugs and salts of any of the compounds that are a heterobifunctional, pan selectin antagonist comprised of a selectin antagonist linked to a benzy amino sulfuric acid (BASA)  and mimicking the native glycosulfopeptide ligand for E and P – selectins.

1070 is a rationally designed glycomimetic inhibitor of E-, P- and L-selectins that interferes in a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.

Field of Use
1070 is initially being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease.

IPSCIO Record ID: 182112

License Grant
Licensor hereby grants to Licensee perpetual, irrevocable worldwide, royalty-bearing right and license under the Licensor Technology to research, Develop, manufacture, have manufactured, use and Commercialize the Licensed Products in and for the Field.
License Property
This program is for a TR Beta.  Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines

“TR-Beta Compounds” means Metabasis’ MB07811 and MB10866 compounds, and any other compounds comprised by the TR-Beta Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.

Field of Use
“Field” means all therapeutic and diagnostic uses in humans or animals.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.